Back to results
US 2016/0108126 A1Published application
CD20 Antibodies and Uses Thereof
AssigneeImmunoGen, Inc.
InventorsJutta DECKERT, Lingyun Rui, Peter U. Park
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeImmunoGen, Inc.
InventorsJutta DECKERT, Lingyun Rui, Peter U. Park
Estimating the term…
CD20 is a transmembrane protein of the tetra-spanin family expressed on the surface of B-cells from peripheral blood as well as lymphoid tissues. CD20 expression persists from the early pre-B cell stage until the plasma cell differentiation stage. In addition to expression in normal B-cells, CD20 is expressed in B-cell derived malignancies such as non-Hodgkin's lymphoma (NHL) and B-cell chronic lymphocytic leukemia (CLL). The present invention includes anti-CD20 antibodies and antigen-binding fragments thereof comprising a light chain variable region and a heavy chain variable region, wherein the CDR-L1, CDR-L2, and CDR-L3 of said light chain variable region comprise the amino acid sequences of SEQ ID NOs: 17-19, respectively, and wherein the CDR-H1, CDR-H2, and CDR-H3 of said heavy chain variable region comprise the amino acid sequences of SEQ ID NOs: 20-22, respectively.
(canceled)
The method of claim 75, wherein said antibody or antigen-binding fragment thereof is murine, humanized, chimeric, resurfaced or human.
The method of claim 75, wherein the antibody or antigen-binding fragment thereof is monoclonal or single-chain.
4-12. (canceled)
The method of claim 95, wherein said cytotoxic agent is selected from the group consisting of a maytansinoid, maytansinoid analog, benzodiazepine, taxoid, CC-1065, CC-1065 analog, duocarmycin, duocarmycin analog, calicheamicin, dolastatin, dolastatin analog, auristatin, tomaymycin derivative and leptomycin derivative or a prodrug of the cytotoxic agent.
14-73. (canceled)
A method for inhibiting the growth of a cancer cell comprising contacting said cell with an antibody or antigen-binding fragment thereof that specifically binds to CD20, wherein said antibody or fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein the CDR1, CDR2, and CDR3 of said heavy chain variable region and the CDR1, CDR2, and CDR3 of said light chain variable region comprise the polypeptide sequences:
A method for treating a patient having a cancer comprising administering to said patient an effective amount of the antibody or antigen-binding fragment thereof that specifically binds to CD20, wherein said antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein the CDR1, CDR2, and CDR3 of said heavy chain variable region and the CDR1, CDR2, and CDR3 of said light chain variable region comprise the polypeptide sequences:
76-78. (canceled)
80-90. (canceled)
The method of claim 95, wherein the linker is linker selected from the group consisting of a disulfide group, a thioether group, an acid labile group, a photolabile group, a peptidase labile group, and an esterase labile group.
Dependencies are inferred from the claim text.